The history of Viagra presents a intricate picture for shareholders. While the initial launch generated significant returns, the lapse of its intellectual property protection opened the floodgates to off-brand competitors, dramatically eroding sales. This poses a particular dilemma for firms relying on related blockbuster offerings, suggesting that

The legacy of Viagra, and its developer copyright, presents a challenging case study for investors. Originally a blockbuster drug, yielding billions in income, its patent expiration created a wave of lower-priced alternatives , significantly eroding its position . While some pharmaceutical companies may try to capitalize on related treatments , the